What Happened?

Shares of radiation safety company Mirion (NYSE: MIR) jumped 3.6% in the afternoon session after an analyst at Robert W. Baird raised their price target on the shares. The firm increased its price objective on the nuclear measurement and analysis company to $22.00 from $20.00, while maintaining an "outperform" rating on the stock. This new target suggests a potential upside of nearly 7% from the stock's previous closing price. The "outperform" rating indicates that the analyst expects Mirion's stock to perform better than the average return of the broader market. This vote of confidence from Wall Street follows a period of positive momentum for the company, which operates in the nuclear energy, medical, and science sectors. The move signals growing optimism about Mirion's future performance and its position within the expanding nuclear energy industry.

After the initial pop the shares cooled down to $20.89, up 3.3% from previous close.

Is now the time to buy Mirion? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Mirion’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

Mirion is up 23.5% since the beginning of the year, and at $20.89 per share, it is trading close to its 52-week high of $21.71 from June 2025. Investors who bought $1,000 worth of Mirion’s shares at the IPO in August 2020 would now be looking at an investment worth $2,100.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.